- Home
- BDRX vs OGEN Comparison
BDRX vs OGEN Comparison
Compare BDRX & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- OGEN
- Stock Information
- Founded
- BDRX 2000
- OGEN 1996
- Country
- BDRX United Kingdom
- OGEN United States
- Employees
- BDRX N/A
- OGEN N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- OGEN Health Care
- Exchange
- BDRX Nasdaq
- OGEN Nasdaq
- Market Cap
- BDRX 5.8M
- OGEN 2.5M
- IPO Year
- BDRX N/A
- OGEN N/A
- Fundamental
- Price
- BDRX $0.88
- OGEN $1.48
- Analyst Decision
- BDRX
- OGEN
- Analyst Count
- BDRX 0
- OGEN 0
- Target Price
- BDRX N/A
- OGEN N/A
- AVG Volume (30 Days)
- BDRX 3.1M
- OGEN 1.1M
- Earning Date
- BDRX 04-11-2025
- OGEN 08-08-2025
- Dividend Yield
- BDRX N/A
- OGEN N/A
- EPS Growth
- BDRX N/A
- OGEN N/A
- EPS
- BDRX N/A
- OGEN N/A
- Revenue
- BDRX N/A
- OGEN N/A
- Revenue This Year
- BDRX N/A
- OGEN N/A
- Revenue Next Year
- BDRX N/A
- OGEN N/A
- P/E Ratio
- BDRX N/A
- OGEN N/A
- Revenue Growth
- BDRX N/A
- OGEN N/A
- 52 Week Low
- BDRX $0.78
- OGEN $1.35
- 52 Week High
- BDRX $41.50
- OGEN $75.60
- Technical
- Relative Strength Index (RSI)
- BDRX 38.47
- OGEN 27.11
- Support Level
- BDRX $0.82
- OGEN $1.39
- Resistance Level
- BDRX $0.90
- OGEN $1.58
- Average True Range (ATR)
- BDRX 0.08
- OGEN 0.33
- MACD
- BDRX 0.01
- OGEN -0.19
- Stochastic Oscillator
- BDRX 12.26
- OGEN 4.14
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.